PLEASE READ THE FULL DESCRIPTION ATTACHED.
Have you been prescribed hormone therapy for breast cancer (tamoxifen or aromatase inhibitors) within the last 5 years? Would you be willing to help researchers develop a support package for women with breast cancer? If so, we would greatly appreciate your help…
The SWEET study group (SWEET: S upporting w omen with adh e rence to adjuvant e ndocrine t herapy following breast cancer)
We are researchers working across a number of universities including Oxford Brookes University and Newcastle University who are developing a support package to help women who are prescribed hormone therapy (tamoxifen or aromatase inhibitors, for example Aromasin, Arimidex, Femara), following a diagnosis of breast cancer, to continue taking it regularly for the recommended period of time. We want to make sure the support package meets women’s needs. Therefore, we would like to speak to women like you, who have been prescribed hormone therapy for breast cancer within the last 5 years (whether you chose to take it or not), to get your views on the package.
For further information, and to register your interest, please contact:
Dr Lucy McGeagh, lmcgeagh@brookes.ac.uk